Whereas in advanced colorectal and lung cancer KRAS and BRAF mutations are predictive of worse clinical outcome [73,74], Gershenson et al. [75] reported a better OS in the 21 patients whose LGSOCs contained a KRAS or BRAF mutation compared to the 58 patients whose LGSOCs had no KRAS or BRAF mutations (median = 106.7 versus 66.8 months, HR = 0.49, 95% CI = 0.26–0.95; p = 0.03). The gene discussed is BRAF; the disease is lung carcinoma.